Head-to-head evidence
Ebronucimab vs SYH2053
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Ebronucimab
Developed by Akeso
NCT05255094 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 464 participants, providing a strong experimental design. However, its primary endpoint was a laboratory lipid measure rather than a hard clinical outcome, and the registry does not report whether the comparison was favorable or statistically significant.
SYH2053
Developed by CSPC Pharmaceutical Group
NCT07421232 · Phase 2 · completed
The trial was randomized and participant-blinded, with placebo and inclisiran comparator groups, and enrolled 156 participants. Its primary endpoint was the clinically accepted LDL-C measure, but the outcome comparison cannot yet be assessed because results are not available.
Next expected readout: December 2027 · NCT07421284 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ebronucimab's landscape · SYH2053's landscape